CyPath Lung Sales Double in Q3 as Physician Adoption Surges 89%
BIAF sits 39% above its 52-week low of $4.56.
Summary
bioAffinity Technologies reported Q3 2026 CyPath Lung sales grew over 100% year-over-year, with 1,620 tests delivered versus 775 in the prior-year period. Ordering physicians jumped 89% and existing prescribers increased utilization by 48%. The company also announced a new distribution agreement with AvMEDICAL targeting the VA and government healthcare system. This follows a 216% test volume surge in Q2 and a recent 1-for-15 reverse split to regain Nasdaq compliance. The growth is material for a company with a $7.2M market cap and a going concern warning, but the press release lacks revenue figures, so the financial impact remains unquantified.
At the time of this announcement, BIAF was trading at $6.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $4.56 to $80.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.